This article is more than 5 years old. Information may no longer be current.

Artificial intelligence enterprise gains partner in colon cancer screening development

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WASHINGTON — In this exclusive video perspective from Digestive Disease Week 2018, the founder of ai4gi Solutions Inc., a commercial joint venture between Satis Operations and Imagia that aims to design artificial intelligence for improved gastrointestinal cancer screening, announced a codevelopment agreement with Olympus.

“Artificial intelligence is really making huge changes in many of the spaces and is coming to medicine quite quickly, so the idea that we can do this with Olympus and bring it to a field that is close to my heart is very exciting for us and we're happy to begin,” Michael Byrne, MD (Cantab), MRCP, FRCPC, told Healio Gastroenterology and Liver Disease.

The goal of the ai4gi, in collaboration with Olympus, is apply artificial intelligence to medical image analysis for accurate and timely cancer detection and differentiation.

“The opportunity here is huge to improve endoscopic procedures, how we do colonoscopy for colon-cancer screening, and the benefits for patients going forward,” Byrne said.

Disclosure: Byrne is the founder of ai4gi Solutions Inc. and has an ownership interest in Satis Operations.